Support The World's Smartest Network
×

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

DONATE
This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

A Multifaceted Approach to Alzheimer's Disease

Researchers are exploring many avenues to understand and treat this devastating illness.

Published April 23, 2013

A Multifaceted Approach to Alzheimer's Disease

As decades of research have shown, Alzheimer's disease (AD) is not a straightforward process. While AD is a neurological disease, characterized by amyloid plaques and tau tangles in the brain, researchers are increasingly taking interdisciplinary approaches to understand its etiology and possible treatments—targeting a wide variety of biological processes and treatment avenues. Additionally, the Academy's Alzheimer's Disease and Dementia Initiative is bringing together leaders in the academic, industry, and non-profit sectors, seeking collaborative answers to the biggest challenges hindering research and development progress in AD.

Peruse the Academy publications and events below, which cover critical areas of exploration in AD research.

Targeting Synaptic Dysfunction in Alzheimer's Disease
eBriefing

Targeting Synaptic Dysfunction in Alzheimer's Disease

Analyzing dysfunction in the synapse, the regions where two nerve cells meet and communicate, may provide important new insights into the onset and progress of this common form of dementia. This eBriefing presents the work of scientists who are characterizing the changes at the synapse and the effects of diet and exercise on synaptic dysfunction in Alzheimer's disease.

Targeting the Vasculature in Alzheimer's Disease and Vascular Cognitive Impairment
eBriefing

Targeting the Vasculature in Alzheimer's Disease and Vascular Cognitive Impairment

In this eBriefing, scientists from academia and industry share their knowledge on pathogenic mechanisms, vascular outcomes in clinical trials, and drug discovery targets for Alzheimer's disease.

Targeting Metals in Alzheimer's and Other Neurodegenerative Diseases
eBriefing

Targeting Metals in Alzheimer's and Other Neurodegenerative Diseases

Researchers investigating Alzheimer's, Parkinson's, and Huntington's diseases met at the Academy to discuss the effect of metals in neurodegenerative diseases—and to highlight clinical achievements using metal-binding compounds to influence disease progression.

Translating Natural Products into Drugs for Alzheimer's and Neurodegenerative Disease
Event

Translating Natural Products into Drugs for Alzheimer's and Neurodegenerative Disease

Monday, May 6, 2013 | 8:15 AM–4:00 PM
Alzheimer's disease may benefit from the novel chemistries found in natural products. This conference explores drug discovery from natural products, including novel approaches and technologies, and promising Alzheimer's drug discovery programs.

Accelerating Translational Neurotechnology: Fourth Annual Aspen Brain Forum
Event

Accelerating Translational Neurotechnology: Fourth Annual Aspen Brain Forum

September 18–20, 2013
Explore innovative models for advancing the translation of novel neurotechnologies (such as neurostimulation, brain-computer interfaces, and neuron replacement therapies) into diagnostic tools and treatments for neurological and psychiatric disease. The conference will feature a breakout session on Alzheimer's disease. Register by August 9 for early-bird discounts.

Alzheimer's Disease Summit: The Path to 2025
Event

Alzheimer's Disease Summit: The Path to 2025

November 6–7, 2013
Speakers will put forth a plan to prevent and effectively treat Alzheimer's by 2025 by accelerating the R&D pipeline via new models of precompetitive collaboration, innovative models of financing, and more rapid adoption of digital technology. Register by September 20 for early-bird discounts.


About the New York Academy of Sciences
The New York Academy of Sciences is an independent, not-for-profit organization that since 1817 has been committed to advancing science, technology, and society worldwide. With 25,000 members in 140 countries, the Academy is creating a global community of science for the benefit of humanity. The Academy's core mission is to advance scientific knowledge, positively impact the major global challenges of society with science-based solutions, and increase the number of scientifically informed individuals in society at large. Please visit us online at www.nyas.org.